With funding from charity Kidney Research UK, Dr Carl May from Bristol Medical School and his team have identified a new treatment pathway for patients with non-genetic (idiopathic) nephrotic syndrome ...

Early first-line anti-CD20 use enabled immunosuppression withdrawal while maintaining disease control in frequently relapsing nephrotic syndrome.

Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker released in response to tubular injury, may serve as a noninvasive tool for measuring kidney injury. A new systematic review and ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...

A new post hoc analysis from the STARMEN trial suggested that the combined assessment of 24-hour proteinuria, creatinine levels, and immunologic response at 3 months post-immunosuppressive therapy ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what about patients ...

A study, presented at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome. The study is also published ...

Children with frequently relapsing or steroid-dependent nephrotic syndrome had a significantly longer relapse-free survival period with tacrolimus than with mycophenolate mofetil. Relapse-free ...

In a small observational study, telitacicept use was associated with improvement in renal and hematologic parameters in patients with lupus nephritis and nephrotic syndrome. Telitacicept use is ...

For children with nephrotic syndrome, there was no difference in time to relapse between two commonly used non-steroid immunosuppressive medications, according to an observational study that emulated ...

The anticipated increase in the nephrotic syndrome market size is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition. Additionally, the ...